Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

598
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
598
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

485
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
485
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

122
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
122
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

669
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
669
Angina IV: Management01:26

Angina IV: Management

435
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
435

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperkalemia and its treatment: real-world evidence and managed care considerations supporting use of potassium binders.

The American journal of managed care·2026
Same author

Pathways to the Quintuple Aim: The Role of Advanced Practice Clinicians in Valvular Heart Disease.

JACC. Advances·2026
Same author

Correction to: Hyperkalemia in heart failure with reduced ejection fraction: implications and management.

Heart failure reviews·2026
Same author

Assessing pharmacists' knowledge and practices involving dietary supplement omega-3 fatty acids.

Journal of clinical lipidology·2025
Same author

Corrigendum to 'Pragmatic approach to temporary mechanical circulatory support in acute right ventricular failure' [J Heart Lung Transplant (2024) 1894-1904].

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same author

Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management.

Heart failure reviews·2025

Related Experiment Video

Updated: Apr 11, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K

Management Strategies for Clopidogrel Hypersensitivity.

Craig J Beavers1, Nicolas W Carris, Kathryn M Ruf

  • 1Cardiovascular Clinical Pharmacy, TriStar Centennial Medical Center, University of Tennessee College of Pharmacy, 3200 Patterson Street, Nashville, TN, 37203, USA, craig.beaverspharmd@gmail.com.

Drugs
|June 10, 2015
PubMed
Summary

Clopidogrel hypersensitivity reactions, often occurring around day 5, pose a clinical challenge. This study provides management recommendations considering reaction types, diagnostic limitations, and treatment strategies like corticosteroids or alternative P2Y12 inhibitors.

More Related Videos

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
10:22

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Published on: September 16, 2011

34.3K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

5.1K

Related Experiment Videos

Last Updated: Apr 11, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.2K
Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity
10:22

Basophil Activation Test for Investigation of IgE-Mediated Mechanisms in Drug Hypersensitivity

Published on: September 16, 2011

34.3K
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

5.1K

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Immunology

Background:

  • Clopidogrel is a vital antiplatelet medication used in dual antiplatelet therapy.
  • Hypersensitivity reactions to clopidogrel can limit its clinical application and present management difficulties.
  • Understanding the mechanisms and presentation of clopidogrel hypersensitivity is crucial for effective patient care.

Purpose of the Study:

  • To develop evidence-based recommendations for managing hypersensitivity reactions to clopidogrel.
  • To evaluate the etiology, pathophysiology, and potential management strategies for clopidogrel hypersensitivity.
  • To provide clinicians with guidance on addressing this significant clinical challenge.

Main Methods:

  • Review of the literature on clopidogrel hypersensitivity, including its mechanisms and clinical presentations.
  • Analysis of diagnostic limitations, particularly for type IV delayed hypersensitivity reactions.
  • Evaluation of proposed management strategies: corticosteroids, desensitization, alternative P2Y12 inhibitors, and avoidance.

Main Results:

  • Clopidogrel hypersensitivity reactions typically manifest around day 5, with generalized, localized, or systemic presentations.
  • Conventional allergy testing methods are often unreliable for detecting type IV delayed reactions.
  • Multiple management strategies exist, each with varying safety, efficacy, and cost profiles.

Conclusions:

  • Effective management of clopidogrel hypersensitivity requires careful consideration of the reaction's characteristics and available treatment options.
  • Clinicians must weigh the risks and benefits of corticosteroids, desensitization, alternative P2Y12 inhibitors, or clopidogrel avoidance.
  • Further research may be needed to optimize diagnostic and therapeutic approaches for clopidogrel hypersensitivity.